Key Points
- William John Sibold sold 2,400 shares on Dec. 4 at an average price of $575.34 for $1,380,816, trimming his stake to 150,074 shares (a 1.57% reduction); the trade was disclosed on an SEC Form 4.
- Madrigal has a $13.28 billion market cap and recently reported a large EPS miss (‑$5.08 vs. est. ‑$2.01), but analysts remain largely bullish — 13 Buy ratings, a "Moderate Buy" consensus and a $553.50 average target with several firms raising targets into the $600s.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CEO William John Sibold sold 2,400 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $575.34, for a total value of $1,380,816.00. Following the sale, the chief executive officer directly owned 150,074 shares of the company's stock, valued at approximately $86,343,575.16. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
William John Sibold also recently made the following trade(s):
- On Tuesday, September 9th, William John Sibold sold 7,279 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $445.63, for a total transaction of $3,243,740.77.
Madrigal Pharmaceuticals Stock Performance
Shares of NASDAQ:MDGL opened at $584.94 on Friday. The company has a current ratio of 3.44, a quick ratio of 3.26 and a debt-to-equity ratio of 0.54. The company has a 50-day moving average price of $485.24 and a 200-day moving average price of $391.04. The company has a market cap of $13.28 billion, a price-to-earnings ratio of -44.96 and a beta of -1.04. Madrigal Pharmaceuticals, Inc. has a 12 month low of $265.00 and a 12 month high of $605.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing analysts' consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 41.50% and a negative net margin of 39.04%. As a group, equities analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.
Analyst Ratings Changes
Several analysts have commented on MDGL shares. HC Wainwright raised their price objective on shares of Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the stock a "buy" rating in a report on Friday, November 21st. Oppenheimer lifted their price target on Madrigal Pharmaceuticals from $600.00 to $650.00 and gave the company an "outperform" rating in a research report on Thursday, November 20th. TD Cowen increased their price objective on Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the stock a "buy" rating in a report on Tuesday, August 26th. Truist Financial raised their price objective on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a "buy" rating in a research report on Wednesday, November 19th. Finally, Cowen reaffirmed a "buy" rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, August 26th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Madrigal Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $553.50.
Get Our Latest Research Report on MDGL
Institutional Investors Weigh In On Madrigal Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the company. Mather Group LLC. purchased a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter worth approximately $33,000. Global Retirement Partners LLC boosted its stake in Madrigal Pharmaceuticals by 221.7% in the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 51 shares in the last quarter. First Horizon Corp acquired a new stake in Madrigal Pharmaceuticals in the third quarter valued at approximately $34,000. AlphaQuest LLC grew its holdings in Madrigal Pharmaceuticals by 412.5% in the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 66 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Madrigal Pharmaceuticals during the third quarter worth $39,000. Hedge funds and other institutional investors own 98.50% of the company's stock.
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
